SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting
Author:
Lyke Kirsten E.,Atmar Robert L.,Islas Clara Dominguez,Posavad Christine M.,Szydlo Daniel,PaulChourdhury Rahul,Deming Meagan E.,Eaton Amanda,Jackson Lisa A.,Branche Angela R.,Sahly Hana M. El,Rostad Christina A.,Martin Judith M.,Johnston Christine,Rupp Richard E.,Mulligan Mark J.,Brady Rebecca C.,Frenck Robert W.,Bäcker Martín,Kottkamp Angelica C.,Babu Tara M.,Rajakumar Kumaravel,Edupuganti Srilatha,Dobrzynski David,Coler Rhea N.,Archer Janet I.,Crandon Sonja,Zemanek Jillian A.,Brown Elizabeth R.,Neuzil Kathleen M.,Stephens David S.,Post Diane J.,Nayak Seema U.,Roberts Paul C.,Beigel John H.,Montefiori David,
Abstract
AbstractAs part of an ongoing study assessing homologous and heterologous booster vaccines, following primary EUA series, we assessed neutralization of D614G and Omicron variants prior to and 28 days after boost. Subset analysis was done in six combinations (N = 10/group): four homologous primary-booster combinations included mRNA-1273 two-dose priming followed by boosting with 100-μg or 50-μg mRNA-1273, Ad26.COV2.S single-dose priming followed by Ad26.COV2.S booster and BNT162b2 two-dose priming followed by BNT162b2 boosting; and two heterologous primary-booster combinations: BNT162b2 followed by Ad26.COV2.S and Ad26.COV2.S followed by BNT162b2. Neutralizing antibody (Nab) titers to D614G on the day of boost (baseline) were detected in 85-100% of participants, with geometric mean titers (GMT) of 71-343 in participants who received an mRNA vaccine series versus GMTs of 35-41 in participants primed with Ad26.OV2.S. Baseline NAb titers to Omicron were detected in 50-90% of participants who received an mRNA vaccine series (GMT range 12.8-24.5) versus 20-25% among participants primed with Ad26.COV2.S. The booster dose increased the neutralizing GMT in most combinations to above 1000 for D614G and above 250 for Omicron by Day 29. Homologous prime-boost Ad26.COV2.S had the lowest NAb on Day 29 (D614G GMT 128 and Omicron GMT 45). Results were similar between age groups. Most homologous and heterologous boost combinations examined will increase humoral immunity to the Omicron variant.
Publisher
Cold Spring Harbor Laboratory
Reference5 articles.
1. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. Geneva, Switzerland: World Health Organization; 2021. Accessed December 22, 2021. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern 2. CDC. Science brief: Omicron (B.1.1.529) variant. Atlanta, GA: US Department of Health and Human Services, CDC; updated 12/2/2021. Accessed December 22, 2021. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html 3. CDC. Potential rapid increase of omicron variant infection in the United States. Updated 12/20/2021. Accessed 12/22/2021. https://www.cdc.gov/coronavirus/2019-ncov/science/forecasting/mathematical-modeling-outbreak.html 4. Atmar RL , Lyke KE , Deming ME , Jackson LA , Branche AR , El Sahly HM , Rostad CA , Martin JM , Johnston C , Rupp RE , Mulligan MJ , Brady RC , Frenck RW Jr , Bäcker M , Kottkamp AC , Babu TM , Rajakumar K , Edupuganti S , Dobrzynski D , Coler RN , Posavad CM , Archer JI , Crandon S , Nayak SU , Szydlo D , Zemanek JA , Dominguez Islas CP , Brown ER , Suthar MS , McElrath MJ , McDermott AB , O’Connell SE , Montefiori DC , Earon A , Neuzil KM , Stephens DS , Roberts PC , Beigel JH , DMID 21-0012 Study Group. Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report. medRxiv 2021.10.10.21264827; doi: https://doi.org/10.1101/2021.10.10.21264827 5. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial;Immune Assays Team§; Moderna, Inc. Team; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team; United States Government (USG)/CoVPN Biostatistics Team;Science,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|